Capacity research for medical device contract manufacturing starts with a narrow question: which named supplier, which facility, which validated lines can run your device class now, and where can that site add volume without requalification. A vendor's aggregate square footage is not the same as usable headroom for your program. The practical research path is to document site-level capacity, ask how that capacity is qualified, and then test the answers against a specific launch scenario. This guide follows that sequence using named examples from Viant, EPTAM Precision, Arterex Medical, Cordis Manufacturing Solutions, NIH SEED materials, and an NHLBI Catalyze presentation on preparing for and managing contract organizations [1][2][3][4][5][6].
Define the Capacity Question at Site Level, Not Company Level
Company-level descriptions of capacity tend to obscure the only data that matters for a program. Viant describes itself as a single-source partner with global locations, factory space, cleanroom space, and a vertically integrated medical device contract manufacturing model [1]. Those claims establish scale but do not by themselves tell a buyer whether a particular site can take a new device class. EPTAM Precision similarly describes eight advanced U.S.-based facilities and a disciplined New Product Introduction, or NPI, framework, with a formal Decision Gate authorizing full project start [2]. The research value of such statements lies in what they make auditable: a named location, a named process stage, and a point at which resource commitments are reviewed.
Capacity questions should therefore be phrased per site and per device class. Arterex Medical, writing about injectable drug delivery programs, states that programs should ask which class, at which site, and which assembly lines are running validated commercial product now [3]. This wording is useful because it excludes future capacity, pilot lines, and unqualified equipment from the answer. A supplier that replies with total square feet or total cleanroom area has not answered the question. The same source notes that asking where the headroom sits means requesting cleanroom floor available for expansion and whether physical space and utilities are provisioned for additional molding or assembly equipment [3]. Site-level questions convert marketing-scale claims into planning data.
Separate Announced Capacity from Qualified Capacity
A central error in capacity research is treating announced construction as available capacity. Arterex Medical reports that MGS opened a 300,000 square foot facility in Richfield, Wisconsin in February 2026, including a 140,000 square foot ISO Class 8 cleanroom [3]. The source adds that much of the announced capacity will not be fully available for years, which it identifies as the part of the story that matters most to a program planning a launch [3]. The publication also cites June 2026 reporting that a commercial facility takes roughly two years to construct, followed by another three to six months for process validation, with a new fully qualified commercial line typically requiring 18 to 24 months to commission [3].
These timing figures should not be treated as universal. They come from Arterex Medical's commentary on injectable device programs and describe that setting, not all device classes [3]. The general principle is nonetheless transferable: a capacity answer must distinguish between building shell, installed equipment, validated process, and running commercial line. A researcher can ask a supplier to provide the qualification status of each line named in a proposal. If the answer is expressed only as future capacity or total investment, the documented engineering risk is that the gap between announcement and validated product will consume the launch window. EPTAM's NPI description offers one way to test that status because its development stage includes validation protocols, process qualification, and confirmation of customer acceptance of validation builds before go-live [2].
A Capacity Questionnaire You Can Administer Now
For each shortlisted facility, request written answers to four questions. First, which assembly lines are running validated commercial product for your device class today, and at what annualized throughput? Second, how much cleanroom floor is available for expansion, with utilities provisioned for additional molding or assembly equipment, and what is the commissioning timeline for those bays [3]? Third, where is the tool room relative to the presses, and what is its operating schedule [3]? Fourth, which documented quality-system elements cover the relevant standards for this device, including any April 2026 ISO 11608 amendments if the program uses needle-based injection systems [3]? Request answers by site, not by company, and record the qualification status of each line. If a supplier describes capacity as future availability, ask for the validation milestone dates that will change that status, using EPTAM's described progression from validation protocols to customer acceptance of validation builds as one example of the sequence to confirm [2].
Add the Regulatory Layer Before Comparing Suppliers
Capacity planning for devices supplied as part of a combination product has a regulatory overlay that square footage discussions often skip. Arterex Medical states that 21 CFR Part 4 Subpart A governs current good manufacturing practice requirements for combination products, and that the only FDA guidance addressing those requirements directly remains the final guidance issued in January 2017 [3]. The source also notes that the agency's draft guidance on Essential Drug Delivery Outputs, issued in June 2024, had not been finalized, leaving interpretive uncertainty for programs in development [3]. These are documented regulatory facts, but they do not establish what any specific program must do; that remains a compliance question for the sponsor.
Device standards have moved more recently in this area. Arterex Medical reports that ISO 11608-1:2022 was amended on April 24, 2026, and ISO 11608-3:2022 was amended on April 17, 2026, and describes both as short amendments rather than wholesale revisions [3]. A capacity questionnaire should ask whether the supplier's quality system reflects those amendments for the relevant needle-based injection system, without assuming the amendments impose a specific process change. Cordis Manufacturing Solutions states that its processes are engineered to meet FDA, MDR, and ISO 13485:2016 requirements, with traceability, compatibility documentation, and audit support [4]. That is a vendor claim about its own system, not evidence that a particular device program will be compliant. Regulatory readiness belongs in the research file as a documented claim to be verified during audit, not accepted from a brochure.
Apply a Concrete Evaluation Scenario
A useful way to compare capacity claims is to run the same hypothetical launch scenario through each supplier's questionnaire. Suppose a program plans an injectable device at 2 million finished units in the first commercial year, with a second-year step to 5 million units across two filling lines. For each supplier, the researcher would request the specific validations for those two lines, the cleanroom expansion space behind each line, and the tool room location. Arterex Medical recommends asking about tooling proximity because a tool room operating on the same campus as the presses turns a design change into hours or days, while third-party tooling at distance can turn it into weeks [3]. This scenario is a suggested exercise, not a tested procurement method.
The same scenario can expose how different suppliers describe the same capacity category. Viant portrays a vertically integrated model from prototyping to full-scale production, with materials expertise, extrusion, tooling, automation, device assembly, and micro-molding [1]. Cordis Manufacturing Solutions emphasizes high-precision thermoplastic and fluoropolymer extrusion, proprietary equipment, rapid tooling, and high-volume component production [4]. These are different customer settings: Viant positions itself for OEMs seeking breadth across a device program, while Cordis positions itself for interventional component supply [1][4]. The research task is not to choose a winner in the abstract but to determine which supplier can answer the site, line, validation, and headroom questions for the stated device class. Where no answer is documented, that absence is itself a finding.
Document What the Evidence Cannot Prove
Several limits constrain the research record. Viant's site presents percentages and aggregate figures for factory and cleanroom space without site-by-site detail in the captured material [1]. EPTAM's NPI white paper is a two-author vendor document, and its case studies and outcomes are described only as section titles in the retrieved text, not as quantified public results [2]. Arterex Medical's capacity math is a published industry commentary dated August 14, 2025, and its references to June 2026 reporting are not accompanied in the captured text by the underlying construction data [3]. Cordis's brochure states production and inspection of millions of components per year and lists tolerances, but it does not provide an audit trail for those figures [4]. Each claim is therefore best recorded as a vendor assertion to be verified in audit.
The NIH SEED checklist is an informational document based on collective experience working with the NIH innovator community, not a regulatory standard or a measured market survey [5]. The NHLBI Catalyze presentation on preparing for and managing contract organizations identifies common outsourcing errors, including poor handling of unanticipated project delays and manufacturing capacity constraints [6]. It also lists using only one contract manufacturer for long-term production as a mistake [6]. These sources describe risks for researchers to investigate, not evidence that any particular supplier will fail. A capacity report should state clearly which findings are documented facts, which are named vendor claims, and which are open questions for a site audit.
Sources & references
- Medical Device Contract Manufacturing: Single-Source Partner | Viant · viantmedical.com
- Medical Device NPI: Best Practices for OEM’s · eptam.com
- Drug Delivery Device Manufacturing Capacity: The 2026 Picture · arterexmedical.com
- Expertise, Quality, Delivered at Scale. - Cordis · cordis.com
- Innovator Checklist for Finding Contract Manufacturing Organization (CMO) · seed.nih.gov
- Preparing for and Managing Contract Organizations in the Development of Medical Devices · www.nhlbicatalyze.org
- Interview: GLP-1 Demand and the New Reality of Device Manufacturing Capacity | ONdrugDelivery · ondrugdelivery.com